Loading...
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: Analysis from the EMPHASIS-HF trial
Girerd, Nicolas Collier, Tim J. Pocock, Stuart J. Krum, Henry McMurray, John J. V. Swedberg, Karl Van Veldhuisen, Dirk J. Vincent, John Pitt, Bertram Zannad, Faiez
Girerd, Nicolas
Collier, Tim J.
Pocock, Stuart J.
Krum, Henry
McMurray, John J. V.
Swedberg, Karl
Van Veldhuisen, Dirk J.
Vincent, John
Pitt, Bertram
Zannad, Faiez
Abstract
Aims: Cardiovascular hospitalization (CVH) in patients with heart failure (HF) is associated with a high post-discharge rate of early re-admission and CV death. Eplerenone might be effective in reducing the incidence of these adverse clinical outcomes during this period. Methods and results: The EMPHASIS-HF trial compared eplerenone with placebo added to standard therapy in 2737 patients with New York Heart Association class II HF and left ventricular ejection fraction ≤35%. We conducted a post hoc analysis in the 2338 patients randomized within 180 days of a CVH. The interaction between the time from the qualifying CVH to randomization and the primary outcome of CV death or hospitalization for HF (HHF), as well as other secondary outcomes, was assessed in Cox survival models. Most of the qualifying CVHs were HHF (N = 1496, 64.0%), acute coronary syndromes (N = 390, 16.7%), and arrhythmias (N = 197, 7.2%). The median time of study drug initiation from qualifying CVH was 42 days. The relative rate reductions in CV death/HHF, HHF, and all-cause mortality were similar (P for interaction = 0.65, 0.44, and 0.40, respectively) whether the treatment was initiated < 42 or 42+ days after qualifying CVH. Absolute rate reductions were −5.61 [−8.67, −2.55] events per 100 patient × years in the < 42 days group and −3.58 [−6.37, −0.79] in the 42+ days group. The adverse effects of eplerenone were also unaffected by the time from the qualifying CVH. Conclusion: Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary syndromes in patients with systolic HF and mild symptoms.
Keywords
eplerenone, systolic heart failure, hospitalization, timing, treatment effect, EMPHASIS-HF
Date
2015
Type
Journal article
Journal
European Heart Journal
Book
Volume
36
Issue
34
Page Range
2310-2317
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled